Search Results - "Hotte, Sebastien J."

A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID‐19) Pandemic: An International Collaborative Group by Al‐Shamsi, Humaid O., Alhazzani, Waleed, Alhuraiji, Ahmad, Coomes, Eric A., Chemaly, Roy F., Almuhanna, Meshari, Wolff, Robert A., Ibrahim, Nuhad K., Chua, Melvin L.K., Hotte, Sebastien J., Meyers, Brandon M., Elfiki, Tarek, Curigliano, Giuseppe, Eng, Cathy, Grothey, Axel, Xie, Conghua

“…The outbreak of coronavirus disease 2019 (COVID‐19) has rapidly spread globally since being identified as a public health emergency of major international…”
Get full text

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies by HOTTE, Sébastien J, HIRTE, Hal W, OZA, Amit M, CHEN, Eric X, SIU, Lillian L, LE, Lyly H, COREY, Alfred, IACOBUCCI, Anne, MACLEAN, Martha, LO, Larry, FOX, Norma Lynn

“…Purpose: Mapatumumab (TRM-1, HGS-ETR1) is a fully human agonistic monoclonal antibody that targets and activates tumor necrosis factor–related…”
Get full text

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial by Mesía, Ricard, Dr Prof, Henke, Michael, Prof, Fortin, Andre, MD, Minn, Heikki, Prof, Yunes Ancona, Alejandro Cesar, MD, Cmelak, Anthony, Prof, Markowitz, Avi B, Prof, Hotte, Sebastien J, MD, Singh, Simron, MD, Chan, Anthony T C, Prof, Merlano, Marco C, MD, Skladowski, Krzysztof, Prof, Zhang, Alicia, PhD, Oliner, Kelly S, PhD, VanderWalde, Ari, MD, Giralt, Jordi, Prof

“…Summary Background Panitumumab is a fully human monoclonal antibody that targets EGFR. We aimed to compare chemoradiotherapy plus panitumumab with…”
Get full text

Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer by CHI, Kim N, HOTTE, Sebastien J, EISENHAUER, Elizabeth A, YU, Evan Y, DONGSHENG TU, EIGL, Bernhard J, TANNOCK, Ian, SAAD, Fred, NORTH, Scott, POWERS, Jean, GLEAVE, Martin E

“…To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in combination with docetaxel/prednisone in patients with metastatic…”
Get full text

Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis by Alibhai, Shabbir M H, Zukotynski, Katherine, Walker-Dilks, Cindy, Emmenegger, Urban, Finelli, Antonio, Morgan, Scott C, Hotte, Sebastién J, Tomlinson, George A, Winquist, Eric

“…Bone health is a significant concern in men with prostate cancer. To evaluate the effectiveness of drug, supplement, and lifestyle interventions aimed at…”
Get full text

Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors by DURAN, Ignacio, HOTTE, Sebastien J, WRIGHT, John J, DANCEY, Janet, SIU, Lillian L, HIRTE, Holger, CHEN, Eric X, MACLEAN, Martha, TURNER, Sandra, LIXIA DUAN, POND, Gregory R, LATHIA, Chetan, WALSH, Scott

“…Purpose: Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities…”
Get full text

Exogenous estrogen therapy, testicular cancer, and the male to female transgender population: a case report by Chandhoke, Gursimran, Shayegan, Bobby, Hotte, Sebastien J

“…Over the last 40 years, there has been a significant increase in the incidence of testicular cancer. The epidemiologic evidence to understand this phenomenon…”
Get full text

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America by Stadler, Walter M., Figlin, Robert A., McDermott, David F., Dutcher, Janice P., Knox, Jennifer J., Miller, Wilson H., Hainsworth, John D., Henderson, Charles A., George, Jeffrey R., Hajdenberg, Julio, Kindwall‐Keller, Tamila L., Ernstoff, Marc S., Drabkin, Harry A., Curti, Brendan D., Chu, Luis, Ryan, Christopher W., Hotte, Sebastien J., Xia, Chenghua, Cupit, Lisa, Bukowski, Ronald M.

“…BACKGROUND: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before…”
Get full text

An Optimized Clinical Regimen for the Oncolytic Virus PV701 by HOTTE, Sébastien J, LORENCE, Robert M, HIRTE, Hal W, POLAWSKI, Susan R, BAMAT, Michael K, O'NEIL, James D, SCOT ROBERTS, M, GROENE, William S, MAJOR, Pierre P

“…Purpose: Previous phase 1 trials of i.v.-administered PV701 have shown this virus to be well-tolerated with toxicity primarily associated with the first dose…”
Get full text

177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice by Chi, Kim N., Yip, Steven M., Bauman, Glenn, Probst, Stephan, Emmenegger, Urban, Kollmannsberger, Christian K., Martineau, Patrick, Niazi, Tamim, Pouliot, Frédéric, Rendon, Ricardo, Hotte, Sebastien J., Laidley, David T., Saad, Fred

“…Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first…”
Get full text

Stereotactic Body Radiation Therapy (SBRT) for a Patient with a Myocardial Metastasis: A Case Report by Dhar, Aneesh, Donovan, Elysia, Leong, Darryl, Hotte, Sebastien J, Swaminath, Anand

“…Metastatic lesions of the heart are rare but have the potential to cause significant morbidity. We describe the case of a patient with renal cell carcinoma who…”
Get full text

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands by AGULNIK, Mark, COHEN, Ezra W. E, BROWN, Shirley, POND, Gregory R, LORIMER, Ian, DANESHMAND, Manijeh, HO, James, TSAO, Ming-Sound, SIU, Lillian L, COHEN, Roger B, CHEN, Eric X, VOKES, Everett E, HOTTE, Sebastien J, WINQUIST, Eric, LAURIE, Scott, HAYES, D. Neil, DANCEY, Janet E

“…Expression of erbB2 and/or epidermal growth factor receptor (EGFR) is associated with biologic aggressiveness and poor prognosis in malignant salivary gland…”
Get full text

Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report by Bondy, Suraya, Tajzler, Camilla, Hotte, Sebastien J, Kapoor, Anil, Zbuk, Kevin, Lalani, Aly-Khan A

“…Li-Fraumeni Syndrome (LFS) is defined by germline mutations of the p53 tumour suppressor gene. Adrenocortical carcinoma (ACC) is a rare aggressive malignancy…”
Get full text

Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction by Voon, Pei Jye, Chen, Eric X, Chen, Helen X, Lockhart, Albert C, Sahebjam, Solmaz, Kelly, Karen, Vaishampayan, Ulka N, Subbiah, Vivek, Razak, Albiruni R, Renouf, Daniel J, Hotte, Sebastien J, Singh, Arti, Bedard, Philippe L, Hansen, Aaron R, Ivy, S Percy, Wang, Lisa, Stayner, Lee-Anne, Siu, Lillian L, Spreafico, Anna

“…Trametinib is an oral MEK 1/2 inhibitor, with a single agent recommended phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D,…”
Get full text

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy by Choueiri, Toni K, Kluger, Harriet, George, Saby, Tykodi, Scott S, Kuzel, Timothy M, Perets, Ruth, Nair, Suresh, Procopio, Giuseppe, Carducci, Michael A, Castonguay, Vincent, Folefac, Edmund, Lee, Chung-Han, Hotte, Sebastien J., Miller, Wilson H, Saggi, Shruti Shally, Lee, Chung-Wei, Desilva, Heshani, Bhagavatheeswaran, Prabhu, Motzer, Robert J, Escudier, Bernard

“…BackgroundThe role and sequencing of combination immuno-oncology (IO) therapy following progression on or after first-line IO therapy has not been…”
Get full text

The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey by Al-Ezzi, Esmail M, Zahralliyali, Amer, Hansen, Aaron R, Hamilton, Robert J, Crump, Michael, Kuruvilla, John, Wood, Lori, Nappi, Lucia, Kollmannsberger, Christian K, North, Scott A, Winquist, Eric, Soulières, Denis, Hotte, Sebastien J, Jiang, Di Maria

“…Although metastatic germ cell tumor (GCT) is highly curable with initial cisplatin-based chemotherapy (CT), 20-30% of patients relapse. Salvage CT options…”
Get full text

A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer by CHI, Kim N, SIU, Lillian L, DONGSHENG TU, EISENHAUER, Elizabeth, HIRTE, Hal, HOTTE, Sebastien J, KNOX, Jennifer, KOLLMANSBERGER, Christian, GLEAVE, Martin, GUNS, Emma, POWERS, Jean, WALSH, Wendy

“…Purpose: Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment resistance. OGX-011 is a…”
Get full text

Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UK by Gonzalez, Juan Marcos, Ganguli, Arijit, Morgans, Alicia K., Tombal, Bertrand F., Hotte, Sebastien J., Suzuki, Hiroyoshi, Bhadauria, Hemant, Oh, Mok, Scales Jr, Charles D., Wallace, Matthew J., Yang, Jui-Chen, George, Daniel J.

“…Background Treatment options for patients with metastatic hormone-sensitive prostate cancer (mHSPC) have broadened, and treatment decisions can have a…”
Get full text

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial by Sternberg, Cora N, Dr, Castellano, Daniel, MD, Daugaard, Gedske, Prof, Géczi, Lajos, MD, Hotte, Sebastien J, MD, Mainwaring, Paul N, MD, Saad, Fred, Prof, Souza, Ciro, MD, Tay, Miah H, MD, Garrido, José M Tello, MD, Galli, Luca, MD, Londhe, Anil, PhD, De Porre, Peter, MD, Goon, Betty, BS, Lee, Emma, PhD, McGowan, Tracy, MD, Naini, Vahid, PharmD, Todd, Mary B, DO, Molina, Arturo, MD, George, Daniel J, MD

“…Summary Background In the final analysis of the phase 3 COU-AA-301 study, abiraterone acetate plus prednisone significantly prolonged overall survival compared…”
Get full text

Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel by Papp, Kim A., Melosky, Barbara, Sehdev, Sandeep, Hotte, Sebastien J., Beecker, Jennifer R., Kirchhof, Mark G., Turchin, Irina, Dutz, Jan P., Gooderham, Melinda J., Gniadecki, Robert, Hong, Chih-ho, Lambert, Jo, Lynde, Charles W., Prajapati, Vimal H., Vender, Ronald B.

“…Background Patients with treated solid tumours (TSTs) are a highly heterogeneous population at an increased risk for malignancy compared with the general…”
Get full text